Causaly – a leading AI platform for biomedical research – recently announced it closed $60 million in Series B funding led by ICONIQ Growth with participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures, and Visionaries Club. Strategic individuals also participated in the round, including Alex Gorsky (former Chairman and CEO of Johnson & Johnson) and Olivier Pomel (CEO and Co-Founder of Datadog). This latest funding round comes after the company recently tripled revenue and customers, now serving 12 of the top 20 pharma companies. This investment brings the total funding raised to $93 million, which will be utilized to extend Causaly’s product lead and expand commercial relationships, enabling breakthrough therapeutic innovations faster than ever.
Developing a new drug is a challenging process that typically spans over a decade, involving extensive research, development, and rigorous clinical trials. And there is a real urgency to expedite this process for our age’s most complex and unsolved diseases, like Parkinson’s, lung cancer, or multiple sclerosis. Causaly’s AI solution was explicitly designed to untangle this complexity, empowering scientists to deeply understand the underlying disease biology.
Using a hybrid approach that combines a high-tech knowledge graph with the latest advances in generative AI, Causaly enables researchers to conduct deep, unbiased scientific exploration with the level of reproducibility and agency that the process of scientific inquiry demands. And the technology is being adopted at scale by teams of researchers in diverse workflows from target identification to biomarker discovery, with customers including Gilead, Novo Nordisk, Regeneron, the Food and Drug Administration, and the National Institute of Environmental Health Sciences. This result is a 10x productivity gain, novel discoveries, and a higher success rate of preclinical programs.
KEY QUOTES:
“Recent advances in AI open completely new possibilities, and there is a great need for transparent AI systems that science leaders can trust. Knowledge is the lifeblood of research organizations, and we are committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.”
— Yiannis Kiachopoulos, Co-founder and CEO of Causaly
“We are excited to accelerate our platform investments and partner with our customers in ingesting proprietary data to truly transform the way that research is done today.”
— Artur Saudabayev, Co-founder and CTO of Causaly
“The sciences are at a turning point driven by the adoption of AI, and we believe Causaly is a leader in delivering this power to scientists in a highly trusted and verifiable manner. Causaly stands out to us as a uniquely powerful and user-oriented platform applying AI to drive significant productivity gains and commercial impact for many major pharmaceutical companies today. We are thrilled to support the entire Causaly team in their mission to revolutionize the way scientists find, visualize, and collaborate on scientific evidence across pharma, life sciences, and beyond.”
— Caroline Xie, general partner at ICONIQ Growth and newest member of the Causaly board of directors
“Causaly gives scientists the power to solve the world’s biggest challenges like never before. It is one of the clearest real-life applications of AI today. Already rolled out by some of the world’s largest pharmaceutical companies, Causaly is actively accelerating biomedical research now. We’ve been truly impressed with the level of adoption by leading research organizations, who continue to rapidly expand spend on Causaly, underlying the impact the technology is already having on R&D.”
— Carlos Gonzalez-Cadenas, Partner at Index Ventures
